Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD33/CD123/CLL-1 CAR-T in Relapsed/Refractory Myeloid Malignancies
NCT06917105Phase 2Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CLL1/CD33/CD123 CAR-T cells in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Tongji Hospital. Primary endpoint: Incidence of Adverse Events at Day 28. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
CLL1/CD33/CD123 CAR-T cells
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06917105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06917105.